Delivering affordable, high-quality medicines
Sandoz, the generic pharmaceuticals division of Novartis, is a global industry leader, offering affordable, high-quality medicines. It is the third-largest division of Novartis, representing nearly 16% of the Group’s total net sales.
Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position in biosimilars, with three marketed medicines accounting for over half of all biosimilars in the combined regions of North America, Europe, Japan and Australia. Additionally, Sandoz holds the #1 position in generic injectables, ophthalmics, dermatology and anti-infectives, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult scientifically to develop and manufacture than standard generics. Sandoz employs more than 26,500 people worldwide and has sales in over 160 countries, as well as six development centers and a worldwide network of approximately 45 production sites.
Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your healthcare professional about any medical condition or product.
- Amoxicillin/clavulanic acid (Augmentin®)
- Omnitrope (Somatropin®)
- Enoxaparin sodium injection (Lovenox®)
- Acetylcysteine (Fluimucil®)
- Fentanyl (Duragesic®)
- Omeprazole (Prilosec®)
- Lactobacillus (Linex®)
- Tacrolimus (Prograf®)
- Sumatriptan (Imitrex®/Imigran®)
- Atorvastatin (Lipitor®)
- *Product names identified by a "®" are trademarks that are not owned by or licensed to the Novartis Group of companies.